(PDF) Treatment of BCR/Abl-Positive Acute Lymphoblastic

Treatment of BCR/Abl-Positive Acute Lymphoblastic Leukemia in P190 Transgenic Mice With the Farnesyl Transferase Inhibitor SCH66336

Blood - United States

doi 10.1182/blood.v97.5.1399

Full Text

Abstract

Available in full text

Categories

Date

March 1, 2001

Authors

Nora Heisterkamp

George Q. Daley

Publisher

American Society of Hematology

Related search

Nilotinib Treatment in Mouse Models of P190 BCR/Abl Lymphoblastic Leukemia

Molecular Cancer

Cancer Research

Molecular Medicine

English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

English

Effect of a Selective Abl Tyrosine Kinase Inhibitor, STI571, on in Vitro Growth of BCR-ABL-positive Acute Lymphoblastic Leukemia Cells

Cancer Research

English

Immunologic Characterization of the Tumor-Specific BCR-Abl Junction in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

English

Acute Myeloid Leukemia With BCR/ABL Fusion Chimera

Indian Journal of Hematology and Blood Transfusion

English

Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-induced B-Cell Acute Lymphoblastic Leukemia

Clinical Cancer Research

Cancer Research

English

Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice

Cancer Research

English

Quantification of Minimal Residual Disease in Patients With E1a2 BCR-ABL-positive Acute Lymphoblastic Leukemia Using a Real-Time RT-PCR Assay

Cancer Research

English

P210 and P190 BCR-ABL Fusion Transcripts Variants Frequencies Among Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Sudan

International Journal of Biomedical Research

English